Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate
- Autori: Triolo, D.; Craparo, E.; Porsio, B.; Fiorica, C.; Giammona, G.; Cavallaro, G.
- Anno di pubblicazione: 2017
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: Cell uptake; Lipoic acid; Mucin permeation; Polyaspartamide; Polymeric micelles; Sustained release; Anti-Inflammatory Agents; Antioxidants; Beclomethasone; Biocompatible Materials; Bronchi; Cell Survival; Drug Carriers; Epithelial Cells; Ethanol; Ethylenediamines; Humans; Lung; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanoparticles; Particle Size; Peptides; Surface Properties; Thioctic Acid; Drug Delivery Systems; Micelles; Biotechnology; Surfaces and Interfaces; Physical and Theoretical Chemistry; Colloid and Surface Chemistry
- OA Link: http://hdl.handle.net/10447/248383
Abstract
In this paper, the potential of novel polymeric micelles as drug delivery systems for Beclomethasone Dipropionate (BDP) administration into the lung is investigated. These nanostructures are obtained starting from α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), which was subsequently functionalized with O-(2-aminoethyl)-O’-methylpolyethylenglycole (PEG2000), ethylenediamine (EDA) and lipoic acid (LA), obtaining PHEA-PEG2000-EDA-LA graft copolymer. Empty and drug-loaded micelles possess adequate chemical-physical characteristics for pulmonary administration such as spherical shape, slightly positive surface charge and mean size of about 200 nm. Besides, BDP-loaded micelles, obtained with a Drug Loading equal to 5 wt%, result to be stable in physiological-mimicking media, protecting the drug from hydrolysis and giving a sustained drug release profile. Moreover, the micelle-like structure and surface characteristics seems to improve drug permeation through the mucus layer. Finally, it is also demonstrated that BDP-loaded PHEA-PEG2000-EDA-LA micelles are able to increase cell uptake of BDP of about 44 wt% compared to Clenil®on 16-HBE cells and possess an higher biocompatibility in comparison with the same commercial formulation.